Literature DB >> 31921954

Data on the role of cardiac α-actin (ACTC1) gene mutations on SRF-signaling.

Ashraf Yusuf Rangrez1, Lucia Kilian1, Katharina Stiebeling1, Sven Dittmann2, Pankaj Yadav3, Eric Schulze-Bahr2, Norbert Frey1, Derk Frank1.   

Abstract

We recently reported a novel, heterozygous, and non-synonymous ACTC1 mutation (p.Gly247Asp or G247D) in a large, multi-generational family, causing atrial-septal defect followed by late-onset dilated cardiomyopathy (DCM). We also found that the G247D ACTC1 mutation negatively regulated serum response (SRF)-signaling thereby contributing to the late-onset DCM observed in human patients carrying this mutation ("A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes" [1]). There are some ACTC1 mutations known to date, majority of which, though, have not been investigated for their functional consequence. We thus aimed at determining the functional impact of various ACTC1 gene mutations on SRF-signaling using SM22-response element driven firefly luciferase activity assays in C2C12 cells.
© 2019 The Author(s).

Entities:  

Keywords:  ACTC1; Atrial septal defect; Gene mutation; Serum response factor

Year:  2020        PMID: 31921954      PMCID: PMC6950782          DOI: 10.1016/j.dib.2019.105071

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the Data Present data is a preliminary evidence of the differential functional impact ACTC1 genetic mutations on SRF-signaling These data provide a basis molecular cardiologists working on ACTC1 for further evaluation of these ACTC1 mutations for genotype-phenotype correlations Functional differences obtained here highlight the fact that different localizations of known or yet to be identified ACTC1 mutations affect the tertiary structure thereby affecting protein-protein interactions, which needs to be experimentally validated.

Data description

Cardiac α-actin is a fundamental structural protein necessary for the maintenance of myofibrillar integrity of the heart by forming thin filaments with tropomyosin and three troponins (C, I, and T). Several isolated ACTC1 mutations have been reported till date (Fig. 1) causing atrial-septal-defect, dilated and hypertrophic cardiomyopathy (Table 1). Majority of these ACTC1 mutants though have not been investigated for their functional consequence. Based on our findings from G247D mutation on SRF-signaling [1], we aimed here at deciphering the functional impact of ACTC1 genetic mutations on SRF-signaling using SM22-response element driven Firefly luciferase activity assay in C2C12 cells. The data is shown in Fig. 2 and the respective raw and analysed data is provided in a separate excel file.
Fig. 1

Known human ACTC1 gene mutations are depicted pictorially. Mutations are described as the nuclic acid change in the coding DNA and the resulting amino acid change in the protein in brackets. ATG = start codon, c = coding DNA, p = protein, TAA = stop codon, UTR = untranslated region.

Table 1

Location and associated cardiac phenotypes of human ACTC1 gene mutations. Listed are the description of the mutation on DNA and protein level as descripted in this article (and corresponding description according to the reference sequence from the NCBI database), the exon and the protein domain in which the mutation is located and reported cardiac phenotypes. ASD = atrial septal defect, ASD II = ostium secundum atrial septal defect, HCM = hypertrophic cardiomyopathy, LVNCC = left ventricular non compaction cardiomyopathy, MR = mitral regurgitation, RCM = restrictive cardiomyopathy.

coding DNA:nucleotide acid change(NM_005159.5)exonprotein:amino acid change(NP_001091.1)protein domainclinical cardiac phenotypereferences
c.301G>A3p.E99K(p.Glu101Lys)subdomain 1ASD, LVNCC, apical HCM, RCM, MROlson et al. 2000 [2],Arad et al. 2005 [3],Monserrat et al. 2007 [4]
c.373A>G3p.M123V(p.Met125Val)subdomain 1, hydrophobic coreASD-IIMatsson et al. 2008 [5]
c.740G>A5p.G245D(p.Gly247Asp)subdomain 3ASD-II, atrial arrhythmias, late onset DCM,Frank et al. 2019 [6],Rangrez et al. 2019 [1]
c.941G>A6p.R312H(p.Arg314His)subdomain 3, tropomyosin binding siteDCMOlson et al.1998 [7]
c.1088A>G7p.E361G(p.Glu363Gly)subdomain 3, Actinin binding siteDCMOlson et al.1998 [7]
Fig. 2

Relative luciferase activity in C2C12 cells deduced from SM22 reporter-driven firefly luciferase for the human wild-type and ACTC1-mutant proteins. (n = 6/group).

Known human ACTC1 gene mutations are depicted pictorially. Mutations are described as the nuclic acid change in the coding DNA and the resulting amino acid change in the protein in brackets. ATG = start codon, c = coding DNA, p = protein, TAA = stop codon, UTR = untranslated region. Location and associated cardiac phenotypes of human ACTC1 gene mutations. Listed are the description of the mutation on DNA and protein level as descripted in this article (and corresponding description according to the reference sequence from the NCBI database), the exon and the protein domain in which the mutation is located and reported cardiac phenotypes. ASD = atrial septal defect, ASD II = ostium secundum atrial septal defect, HCM = hypertrophic cardiomyopathy, LVNCC = left ventricular non compaction cardiomyopathy, MR = mitral regurgitation, RCM = restrictive cardiomyopathy. Relative luciferase activity in C2C12 cells deduced from SM22 reporter-driven firefly luciferase for the human wild-type and ACTC1-mutant proteins. (n = 6/group).

Experimental design, materials, and methods

Cloning of wild-type and mutant ACTC1

Wild-type human ACTC1 gene was cloned into PDONR221 using Gateway technology (BP clonase II reaction, Life technologies) and subsequently recombined into mammalian expression vector pDEST47 (LR clonase II reaction, Life technologies). Site-directed mutagenesis for ACTC1 single nucleotide variants was performed using QuikChange XL Kit (Stratagene) according to manufacturer's instructions. All the constructs were verified by Sangers sequencing to confirm the ACTC1 genotypes.

Luciferase reporter gene assay

C2C12 cells at the confluency of approximately 50% in 12xwell plates were transfected with either wild-type or one of the mutant ACTC1 plasmids together with SM22-promoter driven Firefly-luciferase construct as well as Renilla luciferase under the control of a thymidine kinase promoter (pRLTK) to normalize for transfection efficiency. Media was changed post 6 h transfections and cells were further incubated for 48 h. Cells were then washed twice with PBS, lysed with 150 μl of the active lysis buffer by shaking the plates on a horizontal plate shaker for 20 min. Luciferase assay was performed with 20 μl of the lysates using dual luciferase reporter assay kit according to the manufacturer's instructions (Promega) in 96-well luminometry plates. Bioluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). All the experiments were performed in hexaplicate and repeated two times.

Specifications Table

SubjectCardiology and Cardiovascular Medicine
Specific subject areaMolecular cardiology (molecular mechanisms of dilated cardiomyopathy)
Type of dataTableGraphFigure
How data were acquiredChemiluminescence was measured photometrically on an Infinite M200 PRO system (Tecan).
Data formatAnalysed
Parameters for data collectionACTC1 gene mutations mentioned in Table 1 were inducted by site directed mutagenesis and used to perform the luciferase activity. Data from all the mutant genes is compared with the wild-type ACTC1 to determine the functional impact of respective mutations.
Description of data collectionC2C12 cells were transfected with either wild-type or one of the mutant ACTC1 together with Renilla-luciferase and Firefly-luciferase. Media was changed post 6 h transfections and cells were further incubated for 48 h. Cells were then washed twice with PBS, lysed with the active lysis buffer and the assay was performed using dual luciferase reporter assay kit (Promega), according to the manufacturer's instructions. Bioluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). All the experiments were performed in hexaplicate and repeated two times.
Data source locationInstitution: University Medical Centre KielCity/Town/Region: KielCountry: Germany
Data accessibilityWith the article
Related research articleRangrez et al., A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes. Biochem Biophys Res Commun. https://doi.org/10.1016/j.bbrc.2019.08.081.

Value of the Data

Present data is a preliminary evidence of the differential functional impact ACTC1 genetic mutations on SRF-signaling

These data provide a basis molecular cardiologists working on ACTC1 for further evaluation of these ACTC1 mutations for genotype-phenotype correlations

Functional differences obtained here highlight the fact that different localizations of known or yet to be identified ACTC1 mutations affect the tertiary structure thereby affecting protein-protein interactions, which needs to be experimentally validated.

  7 in total

1.  Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.

Authors:  T M Olson; V V Michels; S N Thibodeau; Y S Tai; M T Keating
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

2.  Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy.

Authors:  T M Olson; T P Doan; N Y Kishimoto; F G Whitby; M J Ackerman; L Fananapazir
Journal:  J Mol Cell Cardiol       Date:  2000-09       Impact factor: 5.000

3.  Gene mutations in apical hypertrophic cardiomyopathy.

Authors:  Michael Arad; Manual Penas-Lado; Lorenzo Monserrat; Barry J Maron; Mark Sherrid; Carolyn Y Ho; Scott Barr; Ahmad Karim; Timothy M Olson; Mitsohiro Kamisago; J G Seidman; Christine E Seidman
Journal:  Circulation       Date:  2005-11-01       Impact factor: 29.690

4.  A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes.

Authors:  Ashraf Yusuf Rangrez; Lucia Kilian; Katharina Stiebeling; Sven Dittmann; Eric Schulze-Bahr; Norbert Frey; Derk Frank
Journal:  Biochem Biophys Res Commun       Date:  2019-08-18       Impact factor: 3.575

5.  Cardiac α-Actin (ACTC1) Gene Mutation Causes Atrial-Septal Defects Associated With Late-Onset Dilated Cardiomyopathy.

Authors:  Derk Frank; Ashraf Yusuf Rangrez; Corinna Friedrich; Sven Dittmann; Birgit Stallmeyer; Pankaj Yadav; Alexander Bernt; Ellen Schulze-Bahr; Ankush Borlepawar; Wolfram-Hubertus Zimmermann; Stefan Peischard; Guiscard Seebohm; Wolfgang A Linke; Hideo A Baba; Marcus Krüger; Andreas Unger; Philip Usinger; Norbert Frey; Eric Schulze-Bahr
Journal:  Circ Genom Precis Med       Date:  2019-08-20

6.  Alpha-cardiac actin mutations produce atrial septal defects.

Authors:  Hans Matsson; Jacqueline Eason; Carol S Bookwalter; Joakim Klar; Peter Gustavsson; Jan Sunnegårdh; Henrik Enell; Anders Jonzon; Miikka Vikkula; Ilse Gutierrez; Javier Granados-Riveron; Mark Pope; Frances Bu'Lock; Jane Cox; Thelma E Robinson; Feifei Song; David J Brook; Steven Marston; Kathleen M Trybus; Niklas Dahl
Journal:  Hum Mol Genet       Date:  2007-10-18       Impact factor: 6.150

7.  Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects.

Authors:  Lorenzo Monserrat; Manuel Hermida-Prieto; Xusto Fernandez; Isabel Rodríguez; Carlos Dumont; Laura Cazón; Margarita G Cuesta; Carlos Gonzalez-Juanatey; Jesús Peteiro; Nemesio Alvarez; Manuel Penas-Lado; Alfonso Castro-Beiras
Journal:  Eur Heart J       Date:  2007-07-04       Impact factor: 29.983

  7 in total
  2 in total

1.  Proteomic Analysis of Exosomes during Cardiogenic Differentiation of Human Pluripotent Stem Cells.

Authors:  Preeti Ashok; Emmanuel S Tzanakakis
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600

2.  Effect of Actin Alpha Cardiac Muscle 1 on the Proliferation and Differentiation of Bovine Myoblasts and Preadipocytes.

Authors:  Anqi Li; Xiaotong Su; Yuan Tian; Guibing Song; Linsen Zan; Hongbao Wang
Journal:  Animals (Basel)       Date:  2021-12-06       Impact factor: 2.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.